By Thomas Lee
Medtronic Inc. (NYSE: MDT) said patients suffering from atrial fibrillation (AF), or irregular heart quivering, reported significantly less symptoms after using its cryoablation technology.
At the Heart Rhythm Society’s annual scientific conference, the Fridley, Minnesota -based company continued its systematic campaign to scientifically validate its Artic Front Cardiac Cryoablation Catheter system by releasing the latest results from its pivotal STOP AF clinical trial of 275 patients.